Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer
Sera Lim, Yesol Kim, Soo-Been Lee, Hyeok-Gu Kang, Dahyun Kim, Jee Won Park, Daeun Chung, Hyunkyung Kong, Kyung Hyun Yoo, Yonghwan Kim, Wonshik Han, Kyung‐Hee Chun, Jong Hoon Park, Jong Hoon Park, Jong Hoon Park
Abstract
Checkpoint kinase 1 (Chk1) expression is enhanced in most cancers owing to oncogenic activation and constant replicative stress. Chk1 inactivation is a promising cancer therapy, as its inactivation leads to genomic instability, chromosomal catastrophe, and cancer cell death. Herein, we observed that miR-320c, downregulated in triple-negative breast cancer (TNBC) patients, can target Chk1. In addition, downregulated miR-320c expression was associated with poor overall survival in TNBC patients. As Chk1 was associated with the DNA damage response (DDR), we investigated the effect of miR-320c on DDR in TNBC cells. To induce DNA damage, we used platinum-based drugs, especially oxaliplatin, which is most effective with miR-320c. We observed that overexpression of miR-320c in TNBC regulated the oxaliplatin responsiveness by mediating DNA damage repair through the negative regulation of Chk1 in vitro. Furthermore, using a xenograft model, a combination of miR-320c mimic and oxaliplatin effectively inhibited tumor progression. These investigations indicate the potential of miR-320c as a marker of oxaliplatin responsiveness and a therapeutic target to increase the efficacy of chemotherapy in TNBC.